Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older

NCT07365826 is registered in ClinicalTrials.gov with Vaxcyte, Inc. as lead sponsor.

NCT NCT07365826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older
Lead sponsor
Vaxcyte, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 12, 2026
Completion date
March 31, 2027
Enrollment
1,390 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal vaccines